Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on blood transfusion safety and pathogen-protected blood components. These filings offer detailed information on the company’s financial performance, business risks, and corporate governance.
Investors can review current reports on Form 8-K, which Cerus uses to furnish press releases announcing quarterly financial results, such as second and third quarter 2025 earnings. These 8-K filings summarize product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, government contract revenue related to INTERCEPT RBC and other development programs, and updates to annual product revenue guidance.
Cerus’ periodic reports on Form 10-K and Form 10-Q, referenced in company press releases, include sections such as “Risk Factors” that discuss uncertainties related to commercialization of the INTERCEPT Blood System, regulatory approvals for the INTERCEPT RBC system, development of technologies like INT200 and lyophilized IFC, supply chain considerations, and macroeconomic and geopolitical risks.
Through this page, users can also monitor disclosures about board and leadership changes, such as those reported in Form 8-K filings covering director retirements and appointments of new board leadership roles. These documents provide context on the company’s governance structure.
Stock Titan enhances these filings with AI-powered tools that summarize lengthy documents, highlight key items such as revenue trends, development program updates, and risk factor changes, and help readers navigate complex regulatory language. Users can quickly locate information on topics like product revenue composition, government contract funding, and the status of clinical and regulatory programs related to Cerus’ INTERCEPT technologies.
Cerus Corporation reported improved Q1 2026 results, with revenue growing and losses narrowing. Product revenue reached $53.7 million for the three months ended March 31, 2026, up from $43.2 million a year earlier, while government contract revenue was $6.2 million versus $5.6 million.
Loss from operations narrowed to $0.4 million, compared with $5.9 million in the prior-year quarter. Net loss attributable to Cerus was $1.6 million, or $0.01 per share, better than the $7.7 million net loss and $0.04 loss per share a year ago.
Cerus ended the quarter with $27.9 million in cash and cash equivalents, $52.6 million in short-term investments and $0.6 million of restricted cash. Debt totaled $84.9 million, including $52.4 million classified as current. Operating activities used $3.0 million of cash, while investing activities provided $9.9 million mainly from investment maturities.
Cerus Corporation reported strong first quarter 2026 results with higher revenue and a sharply lower net loss. Total revenue was $59.9 million, up 23% from $48.9 million a year earlier, driven by 24% product revenue growth to $53.7 million and 120% demand growth for INTERCEPT Fibrinogen Complex.
Product gross profit rose to $27.9 million, though product gross margin declined to 52.0% from 58.8% due to prior-year one-time benefits and current inflation, currency, and tariff impacts. Operating expenses fell 7% to $34.5 million, helping reduce net loss attributable to Cerus to $1.6 million, or $0.01 per share, from $7.7 million, or $0.04 per share.
The company generated non-GAAP adjusted EBITDA of $4.0 million versus $0.2 million a year earlier and ended March 31, 2026 with $80.4 million in cash, cash equivalents, and short-term investments. Cerus raised its 2026 product revenue guidance to a range of $227 million to $231 million, including IFC revenue between $22 million and $24 million, reflecting expected growth of 10% to 12% from 2025.
Cerus Corporation is asking stockholders to vote at its June 2, 2026 virtual annual meeting on four key items: electing two directors, expanding its 2024 Equity Incentive Plan by 10 million shares, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as auditor for 2026.
The proxy also highlights Cerus’ INTERCEPT Blood System franchise and 2025 results, including $206.1 million in product revenue, a narrowed GAAP net loss of $15.6 million, positive non-GAAP adjusted EBITDA of $9.5 million, and positive operating cash flow for a second year.
Cerus Corporation adopted a new executive severance plan that standardizes payouts for several senior officers if they are terminated without cause or resign for good reason, particularly around a change of control. The plan covers the CFO, COO, Chief Medical Officer and Chief Legal Officer.
Following a qualifying termination within 12 months after a change of control, participants receive a lump sum equal to 18 months of base salary and 1.5 times their target annual cash bonus, along with up to 18 months of paid COBRA premiums and full acceleration of all outstanding equity awards. For Vivek Jayaraman when serving as Chief Executive Officer, these change-of-control severance amounts increase to 24 months of base salary, two times target bonus and up to 24 months of COBRA.
Outside a change of control, the plan provides Mr. Green and Ms. Jensen (and Mr. Jayaraman while COO) with 12 months of salary continuation and up to 12 months of COBRA coverage. If Mr. Jayaraman is President and Chief Executive Officer at the time of a qualifying non-change-of-control termination, he also receives full equity acceleration and, for terminations after September 30, a prorated annual cash bonus based on his target opportunity and time worked.
Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP Chief Financial Officer Kevin Dennis Green received an equity grant of 200,000 shares of common stock. The award was made at a stated price of $0.00 per share as a stock-based compensation grant, not a market purchase or sale.
The grant was issued in the form of restricted stock units, each representing a contingent right to one share of Cerus common stock. These RSUs vest in full one year from the grant date, provided he continues serving the company through that vesting date. Following this grant, he directly holds 1,240,551 common shares.
Jensen Chrystal reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP Chief Legal Officer Chrystal Jensen received a stock-based compensation award. On April 1, 2026, Jensen was granted 200,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share.
The RSUs represent a right to receive one share of common stock for each unit and vest in full one year from the grant date, as long as Jensen remains in continuous service. After this grant, Jensen directly holds 1,146,131 shares of CERUS CORP common stock.
Cerus Corp Schedule 13G/A amendment: The Vanguard Group reports zero beneficial ownership of Cerus Corp common stock following an internal realignment. The filing states that, after the January 12, 2026 realignment, certain Vanguard subsidiaries will report holdings separately and Vanguard no longer is deemed to beneficially own shares held by those subsidiaries.
The filing is signed by Vanguard's Head of Global Fund Administration on March 26, 2026, and lists 0 shares and 0% ownership with no voting or dispositive power.
Soleus Capital Master Fund, L.P. and affiliated filers report beneficial ownership of 9,828,700 shares of Cerus Corporation common stock, representing 5.1% of the class based on 192,171,776 shares outstanding as of February 5, 2026.
The filing indicates shared voting and shared dispositive power over 9,828,700 shares among Soleus entities and Guy Levy. The filers state the shares are held directly by the Master Fund and include a standard disclaimer that affiliated entities and Mr. Levy disclaim beneficial ownership except for purposes of Section 13(d).
Cerus Corp Chief Legal Officer Chrystal Jensen reported an open-market sale of 113,008 shares of Common Stock on March 12, 2025. The weighted average sales price was $1.6572 per share, with individual trades ranging from $1.62 to $1.73 per share.
According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. Following the transactions, Jensen directly holds 946,131 shares of Cerus common stock.